title: Acquired hemophilia masked by warfarin therapy.
abstract: People without hemophilia but with autoantibodies specifically directed against the procoagulant activity of factor VIII are known to have acquired hemophilia. The bleeding diathesis in these patients is often severe and life-threatening. The definite laboratory diagnosis of this disorder includes demonstration of low factor VIII levels in plasma with a high titer of factor VIII inhibitors, but the initial suspicion for its presence should rise in view of a prolonged partial thromboblastin time (PTT) and a normal prothrombin time associated with an acquired bleeding disorder. Oral anticoagulant treatment is known to prolong PTT as well, and the merger of these 2 situations may cause delayed diagnosis of acquired hemophilia with devastating consequences. We describe here the first reported case of acquired hemophilia diagnosed in a patient treated with warfarin. In such patients prolonged PTT may be ascribed to warfarin therapy rather than to acquired hemophilia, thus causing a dangerous delay in diagnosis.
authors.affiliation: Department of Medicine E, Sheba Medical Center, Tel-Hashomer, Israel. unit@netvision.net.il
authors.forename: R
authors.initials: R
authors.lastname: Kantor
authors.forename: H
authors.initials: H
authors.lastname: Mayan
authors.forename: L
authors.initials: L
authors.lastname: Puritz
authors.forename: D
authors.initials: D
authors.lastname: Varon
authors.forename: Z
authors.initials: Z
authors.lastname: Farfel
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects*; D001323:Autoantibodies / Q000097:blood; D001778:Blood Coagulation Disorders / Q000175:diagnosis; D003937:Diagnosis, Differential; D005169:Factor VIII / Q000276:immunology; D005260:Female; D006467:Hemophilia A / Q000097:blood / Q000175:diagnosis* / Q000276:immunology; D006801:Humans; D010314:Partial Thromboplastin Time; D014859:Warfarin / Q000009:adverse effects*
chemical_list: D000925:Anticoagulants; D001323:Autoantibodies; D014859:Warfarin; D005169:Factor VIII